Polymorphisms of the DNA repair gene XPD (751) and XRCC1 (399) correlates with risk of hematological malignancies in Turkish population

被引:0
作者
Ozcan, Ali [2 ]
Pehlivan, Mustafa [3 ]
Tomatir, Ayse Gaye [1 ]
Karaca, E. [4 ]
Ozkinay, Cihangir [4 ]
Ozdemir, Filiz [2 ]
Pehlivan, Sacide [4 ,5 ]
机构
[1] Pamukkale Univ, Fac Med, Dept Med Biol, TR-20070 Denizli, Turkey
[2] Ege Univ, Fac Sci, Dept Biol, TR-35100 Izmir, Turkey
[3] Gaziantep Univ, Fac Med, Dept Hematol, TR-27100 Gaziantep, Turkey
[4] Ege Univ, Genet Dis Res & Applicat Ctr, TR-35100 Izmir, Turkey
[5] Gaziantep Univ, Fac Med, Dept Med Biol, TR-27100 Gaziantep, Turkey
关键词
DNA repair; XPD gene; XRCC1; gene; DNA; PCR-RFLP; ACUTE MYELOID-LEUKEMIA; BLADDER-CANCER RISK; LUNG-CANCER; BREAST-CANCER; LYS751GLN POLYMORPHISM; XERODERMA-PIGMENTOSUM; AFRICAN-AMERICANS; EXCISION-REPAIR; SUSCEPTIBILITY; SMOKING;
D O I
暂无
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Polymorphisms that occur in DNA repair genes affect DNA repair capacity and constitute a risk factor in hematological malignancies. This study, was aimed to investigate whether xeroderma pigmentosum complementation group D (XPD) and x-ray repair cross-complementing group 1 (XRCC1) gene polymorphisms were involved in the susceptibility to different hematological malignancies. The genotype and allele frequencies were obtained by analyzing XPD gene codon 751 in a total of 80 patients and XRCC1 gene codon 399 polymorphism in a total of 100 patients with hematological malignancies and 100 healthy controls. Mean age was 45 (range: 16 to 75) and 46 (range: 16 to 82) in the patients groups and 39.5 (range: 18 to 67) in the control group, respectively. Additionally, distribution of genotypes and alleles were compared in the patient and control groups. In the comparison of genotype and allele frequencies in hematological malignancies and healthy controls, XPD-751Gln variant was arranged and compared according to age and sex and Gln/Gln genotype was reported to be a protector, which was decreased significantly in acute myeloblastic leukemia (AML) (p = 0.042). No relationship was determined between allele frequencies (p = 0.054). In XRCC1-399, it was shown that Gln/Gln genotype was decreased significantly in AML (p = 0.014) plus all hematological malignancies (p = 0.033) and that Gln allele was present at a lower ratio in AML (p = 0.046). The distribution of polymorphism of both genes was not statistically significant in terms of age and sex. In leukemia with early relapse, XPD 751 Lys/Lys genotype was determined at a statistically higher ratio (p = 0.042). In the evaluation of both genes together, a decrease was noted in Gln/Gln + Lys/Gln haplotype frequency in hematological malignancies (p = 0.048). In this study, it was demonstrated that a decrease in Gln/Gln genotype and Gln allele acted as a protector in XPD codon 751 and XRCC1 codon 399 polymorphisms in acute myeloblastic leukemia (AML) and that an increase in Lys/Lys genotype in acute leukemia was associated with early relapse.
引用
收藏
页码:8860 / 8870
页数:11
相关论文
共 58 条
[1]   Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy [J].
Allan, JM ;
Smith, AG ;
Wheatley, K ;
Hills, RK ;
Travis, LB ;
Hill, DA ;
Swirsky, DM ;
Morgan, GJ ;
Wild, CP .
BLOOD, 2004, 104 (13) :3872-3877
[2]   DNA repair polymorphisms modify bladder cancer risk: A multi-factor analytic strategy [J].
Andrew, Angeline S. ;
Karagas, Margaret R. ;
Nelson, Heather H. ;
Guarrera, Simonetta ;
Polidoro, Silvia ;
Gamberini, Sara ;
Sacerdote, Carlotta ;
Moore, Jason H. ;
Kelsey, Karl T. ;
Demidenko, Eugene ;
Vineis, Paolo ;
Matullo, Giuseppe .
HUMAN HEREDITY, 2008, 65 (02) :105-118
[3]   The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens [J].
Artac, Mehmet ;
Bozcuk, Hakan ;
Pehlivan, Sacide ;
Akcan, Songuel ;
Pehlivan, Mustafa ;
Sever, Tugce ;
Ozdogan, Mustafa ;
Savas, Burhan .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (06) :803-809
[4]   XPD gene polymorphism and host characteristics in the association with cutaneous malignant melanoma risk [J].
Baccarelli, A ;
Calista, D ;
Minghetti, P ;
Marinelli, B ;
Albetti, B ;
Tseng, T ;
Hedayati, M ;
Grossman, L ;
Landi, G ;
Struewing, JP ;
Landi, MT .
BRITISH JOURNAL OF CANCER, 2004, 90 (02) :497-502
[5]   Genetic polymorphisms in DNA repair genes and risk of lung cancer [J].
Butkiewicz, D ;
Rusin, M ;
Enewold, L ;
Shields, PG ;
Chorazy, M ;
Harris, CC .
CARCINOGENESIS, 2001, 22 (04) :593-597
[6]   Polymorphisms in DNA repair gene XRCC1 and increased genetic susceptibility to breast cancer [J].
Chacko, P ;
Rajan, B ;
Joseph, T ;
Mathew, BS ;
Pillai, MR .
BREAST CANCER RESEARCH AND TREATMENT, 2005, 89 (01) :15-21
[7]  
Das-Gupta EP, 2000, HEMATOL ONCOL, V18, P99, DOI 10.1002/1099-1069(200009)18:3<99::AID-HON662>3.0.CO
[8]  
2-Z
[9]   Genetic polymorphism of XRCC1 and lung cancer risk among African-Americans and Caucasians [J].
David-Beabes, GL ;
London, SJ .
LUNG CANCER, 2001, 34 (03) :333-339
[10]   Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients [J].
de las Peñas, R ;
Sanchez-Ronco, M ;
Alberola, V ;
Taron, M ;
Camps, C ;
Garcia-Carbonero, R ;
Massuti, B ;
Queralt, C ;
Botia, M ;
Garcia-Gomez, R ;
Isla, D ;
Cobo, M ;
Santarpia, M ;
Cecere, F ;
Mendez, P ;
Sanchez, JJ ;
Rosell, R .
ANNALS OF ONCOLOGY, 2006, 17 (04) :668-675